NRC
CRSP icon

New Republic Capital’s CRISPR Therapeutics CRSP Stock Holding History

New Republic Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$314K Buy
+5,752
New +$303K 0.07% 207

Other funds holding CRSP

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

New Republic Capital's CRSP Position: Q2 2026 in Review

New Republic Capital opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 5,752 shares worth $314K. The stake represents 0.07% of the portfolio and ranks #207 among its holdings.

219 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • New Republic Capital held 5,752 shares of CRISPR Therapeutics worth $314K as of Q2 2026.
  • CRISPR Therapeutics was a new New Republic Capital position in Q2 2026.
  • CRISPR Therapeutics made up 0.07% of New Republic Capital's portfolio in Q2 2026, its #207 holding.
  • 219 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on New Republic Capital's 13F filing for Q2 2026, filed 31 Jul 2026.